Kera Capital Partners’s NovoCure NVCR Stock Holding History

Kera Capital Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$311K	Sell	20,504 -950	-4%	-$14.4K	0.03%	469
2026 Q1	$234K	Buy	21,454 +1,763	+9%	+$22K	0.03%	496
2025 Q4	$244K	Buy	19,691 +9,015	+84%	+$116K	0.03%	469
2025 Q3	$138K	Sell	10,676 -2,643	-20%	-$35.3K	0.02%	411
2025 Q2	$237K	Buy	13,319 +2,453	+23%	+$42.7K	0.05%	273
2025 Q1	$194K	Buy	+10,866	New	+$247K	0.06%	180

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Kera Capital Partners's NVCR Position: Q2 2026 in Review

Kera Capital Partners reduced its NovoCure (NVCR) stake by 4.4% in Q2 2026, selling an estimated $14.4K and leaving 20,504 shares worth $311K. The position accounts for 0.03% of the portfolio, ranked #469.

Kera Capital Partners first reported a position in NVCR in Q1 2025 and has held it in 6 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Kera Capital Partners held 20,504 shares of NovoCure worth $311K as of Q2 2026.
Kera Capital Partners sold 950 NovoCure shares in Q2 2026, an estimated $14.4K.
NovoCure made up 0.03% of Kera Capital Partners's portfolio in Q2 2026, its #469 holding.
Kera Capital Partners first reported a position in NovoCure in Q1 2025 and has held it in 6 quarters since.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.